ANRO
Alto Neuroscience, Inc.17.10
+0.07+0.41%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
531.23MP/E (TTM)
-Basic EPS (TTM)
-2.30Dividend Yield
0%Recent Filings
10-K
FY2025 results
Alto Neuroscience reported FY2025 results for the year ended December 31, 2025, as a clinical-stage biopharma with no revenue disclosed in the 10-K. Pipeline advanced with key milestones: acquired ALTO-207 in May 2025 for TRD, planning Phase 2b in H1 2026; ALTO-300 Phase 2b interim in February 2025 upheld continuation for MDD; ALTO-101 enrollment completed for CIAS POC, topline due Q1 2026. Q4 saw FDA Fast Track for ALTO-101 in October and Chase agreement amendment in December. Cash position stood at $55.2M market value of non-affiliate shares as of June 30, 2025. No capex or free cash flow provided. Pipeline misses remain a threat to momentum.
8-K
2025 results: $177M cash
Alto Neuroscience reported 2025 results on March 16, 2026, with cash at $177M funding operations into 2028, R&D expenses down to $45.6M from $47.0M, yet net loss widened to $63.2M from $61.4M. ALTO-207 acquisition advances TRD via Phase 2b trial starting 1H 2026, backed by Lancet-published 0.87 effect size. Four data readouts loom through 2027. Cash extends to milestones.
8-K
$120M private placement
Alto Neuroscience entered a $120M private placement on March 16, 2026, selling 2.9M common shares at $20.00 and pre-funded warrants for 3.1M shares, expecting gross proceeds before expenses. Funds will advance ALTO-207 through Phase 3 in treatment-resistant depression and potential NDA. Board expands to seven. Closing set for March 17.
8-K
Q3 results, $184M cash runway
Alto Neuroscience reported Q3 2025 results, posting a $14.2M net loss on $10.5M R&D spend, down from prior year. Cash swelled to $184.2M post-$50M PIPE, funding ops into 2028. Pipeline advances: ALTO-207 accelerates to Phase 2b H1 2026 after FDA nod; topline readouts loom for ALTO-101 1Q26, ALTO-300 mid-2026. Strong cash fuels data catalysts.
10-Q
Q3 FY2025 results
Alto Neuroscience narrowed its Q3 operating loss to $15M from $19M y/y, trimming R&D to $10.5M from $13.1M as ALTO-100 and ALTO-203 trials wrapped up, while G&A fell to $4.4M from $5.8M. Cash burned $40M YTD on operations versus $34M last year, leaving $138M in cash and equivalents at quarter-end, bolstered by a $20M term loan (due 2029) and $2M Wellcome grant; free cash flow not disclosed in the 10-Q. Chase M&A closed May 2025 for $3M cash, targeting up to $71.5M contingent milestones and recognizing no goodwill. October's $50M private placement extends runway into 2028. Securities litigation lingers.
IPO
Employees
Sector
Industry
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ANVS
Annovis Bio, Inc.
3.93+0.15
ATAI
Atai Beckley N.V
4.23+0.09
ATHE
Alterity Therapeutics Limited
3.07+0.06
CYBN
Cybin Inc.
6.66+0.00
CYTOF
Altamira Therapeutics Ltd.
0.07+0.00
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
LBRX
LB Pharmaceuticals Inc
19.82-0.04
MNMD
Mind Medicine (MindMed) Inc.
12.26+0.18
NMRA
Neumora Therapeutics, Inc.
1.85-0.11